Long-term data from the phase III PRIMA study showing Zejula (niraparib) maintained a sustained and clinically meaningful PFS benefit as a maintenance therapy in patients with first-line ovarian cancer following a response to platinum-based chemotherapy. Importantly, this benefit was sustained across all biomarker subgroups, including BRCAm, HRd and HRp.
A team led by researchers at the University of Chicago discovered how to block nicotinamide N-methyl transferase, an enzyme that is involved in the progression of high-grade serous ovarian cancer.
